2017 Attendees
2017 Event Partners
2017 attendING COMPANIES INCLUDED
545+ attendees from 375+ companies)
| 4BIO Capital Partners | Kurma Partners |
| Abbvie | L1 Capital / Europe Offering |
| Abingworth | Lakeside Healthcare |
| Ablynx NV | Lakeside Plus |
| Abzena | LBA Ventures |
| Active Needle Technology | Legal & General Investment Management |
| Addex Therapeutics | Levrett PLC |
| AdRem Capital | Life Sciences Hub Wales |
| Advent Life Sciences | Life Sciences Partners |
| Advisory London | LifeSci Advisors |
| Aetas Global Markets | Lightpoint Medical |
| Aglaris Ltd. | Lombard Medical |
| AgPlus Diagnostics | Longevity Venture Partners |
| Alacrita | M-V Arterica |
| Albion Technology & General VCT | Mainstay Medical Limited |
| Albion Ventures | Majid Al Futtaim Trust |
| Allecra Therapeutics | Mann Bioinvest |
| Allergy Therapeutics | Marketing Birmingham |
| Amadeus Capital Partners | Marks & Clerk |
| Amgen | Maven Capital Partners |
| Anima Biotech | Medicine Discovery Catapult |
| Apposite Capital | Medicon SD Ltd |
| Aptamer Group | Medicxi |
| Aptamer Solutions | Medigene |
| Arix Bioscience | MedInnovation |
| Arthurian Life Sciences | MedTech Imperial |
| Artios Pharma | Medtech Insight |
| Artios Therapeutics | Medtronic |
| ASep healthcare | Memcor |
| Astex Pharmaceuticals | Mercia Fund Managemnet |
| Atelix | Mercia technologies |
| Atopix Therapeutics | Merck |
| Atriva Therapeutics | Merck Ventures |
| Auspherix | Meyer & Co |
| Avita Medical | Microbiotix |
| Bactevo | MicroQuin |
| Barclays | Midatech Pharma |
| Beaufort Securities | Miotech Medpartners |
| Belsize Asset Management | MIRABAUD Securities |
| Bergen Asset Management | Mitotech |
| BioCatalyst Capital Partners | Momentum Bioscience |
| BioGeneration Ventures | MP.com |
| Bionow | MRC Technology |
| BioPharm Insight - Mergermarket Group | MSD |
| BioSeed Capital | Multipharma SA |
| Biotech and Money | MVM Life Science Partners |
| Biotech Growth Trust | N+1 Singer |
| BioWorld Today | Nanobiotix |
| Bloomberg | Narec Capital Ltd |
| Boston Scientific Ventures | Nasdaq |
| Brewin Dolphin | Nature Biotechnology |
| Bristows | NeoMed |
| British Expats in Life Sciences | NetScientific |
| British Pharmacological Society | New Hope Investments |
| BROTHERS & Partners Europe | New Mosaic Ltd |
| BWL Investments | New Science Global Healthcare Fund |
| BXR Partners | New Wave Ventures |
| Calcivis | Norgine Ventures Management Limited |
| Cambridge Enterprise | North-East Healthcare Investment |
| Cambridge Enterprise Seed Funds | NovellusDx |
| Cambridge Innovation Capital | Novo A/S |
| Cambridge Medical Robotics | Novo Ventures |
| Cancer Research Technology | NOXXON Pharma |
| Capital Cell | Numis Securities Limited |
| Capital Family Office | O2h Ventures |
| Capital Grand Est. | Odgers Berndtson |
| Capricorn Venture Partners | OION |
| Carrick Therapeutics | Oncopeptides |
| Catapult Ventures | One Nucleus |
| Celixir | Oppilotech |
| Cell and Gene Therapy Catapult | OrbiMed |
| Cell Medica | OrbiMed Healthcare Fund Management |
| Cellnovo | organisationname |
| Censo Biotechnologies | ORI Fund |
| China BlueSky Ventures / BioCapital Impact Fund | Oxford BioMedica |
| Chronos Therapeutics | Oxford Impedance Diagnostics |
| Citigate Dewe Rogerson | Oxford Pharmascience |
| CK2 Partners Ltd | Oxford Technology |
| Clearpath Analysis | Oxford University Innovation |
| Clinigen | Oxon |
| Clubb Capital | Panakes Partners |
| CMS Cameron McKenna | Panmure Gordon & Co. |
| Co-Founder, Wharton Angels Network | Papyrus Therapeutics |
| Coalesce Product Development | Parkure |
| Combat Medical | Partners HealthCare |
| Cooley (UK) LLP | Paul Capital |
| Coulter Partners | PBD Biotech |
| Covington and Burling | Peel Hunt |
| Creabilis | Peptinnovate |
| CREO Medical | Pfizer |
| Crescendo Biologics | Pharma Intelligence |
| Cresset | PharmaPhorum |
| Curasight | PharmaVentures |
| Curetis | Pharmedartis |
| CytoBioscience | Philips Company |
| Danish Growth Capital II | Pragma Therapeutics |
| Deep Knowledge Life Sciences | Precious Cells |
| Deep Knowledge Ventures | Privos Capital |
| Deepbridge Capital | Prokarium |
| Deepbridge Syndicate | ProteoDesign |
| Deltex Medical Group | Proteome Sciences |
| Department for International Trade | PsiOxus Therapeutics |
| Desentum Oy | PsyOmics |
| Discuva | Qbtech |
| Domainex / Canbex Therapeutics | Quanta Dialysis Technologies |
| Drais Pharmaceuticals | RBV Capital |
| Drug Discovery Today | RD-Support |
| e-consultancy | Redline Captal |
| Edesa Biotech | ReNeuron |
| EGB Advisors PR | ReViral |
| Eli Lilly & Co. | Rex Bionics |
| Endeavour Vision | RMI Partners |
| Enso Ventures | Rosetta Capital |
| EP Vantage | Rothschild & Co. |
| Epidarex | Roundcape |
| EQS | Ruffena Capital |
| Ergomed | RX Securities |
| Esperante | Ryan-Kay |
| EURASANTE | Ryboquin |
| Evernow Publishing Ltd | Ryboquin Company |
| Evotec | Sanara Ventures |
| Exonate | Saniona |
| EY | Scancell Holdings |
| F-Prime Capital | SCIAD |
| Family Office | Scottish Equity Partners |
| Fimmic Oy | SCRIP |
| Financial Times | SCRIP Intelligence |
| FIT Biotech | Sensiia |
| Fladgate | Sentinel Oncology |
| Forbion Capital Partners | Seroba Life Sciences |
| Forrest Innovations | Silicon Valley Bank |
| Fort Rock Capital | Sino-UK Fund |
| FreeMind Group | Sixth Element Capital |
| Fresenius Medical Care Ventures | SJB Technical Recruitment |
| Galecto Biotech | Sofinnova Partners |
| Gill Jennings & Every | Solvotrin Therapeutics |
| Glyconics | Springer Nature |
| Glycostem | SR-One |
| GNA Biosolutions | Stent-Tek |
| GR Capital | Stevenage Bioscience Catalyst |
| GreenBone Ortho | Stifel |
| GTL Investments | Sunergos Innovations |
| Hadean Ventures | Sunstone Capital |
| Harbert European Growth Capital | SurgaColl Technologies |
| Haseltine Lake | SV Life Sciences |
| HBM Partners | Syncona |
| HealthCap | Syndicate Room |
| HealthCare Royalty Partners | Takeda Ventures, Inc. (TVI) |
| Heptares Therapeutics | Talentmark |
| Hermes Pacific Capital | Tassi & Co. |
| High-Tech-Gruenderfonds Management | The Mergermarket Group |
| Horizon Discovery | The Pharma Letter |
| IAG | The Research Network |
| ICMBH | The RSA Group |
| Ignite Capital Partners | The SidebySide Partnership |
| iMicroQ | The University of Manchester |
| ImmuPharma | The Wellcome Trust |
| Imperial Innovations | Tigenix |
| Inbio Ventures | Touchstone Innovations |
| Independent | Trinity Delta |
| INKEF Capital | Tulchan Communications |
| Inositec | Tusk Therapeutics |
| Instinctif Partners | TVM Capital Life Science |
| Intralinks | TxCell |
| Inventages | UBM |
| Invention Capital Associates | UCL |
| Investarget | UCL Business |
| Investec Wealth & Investment | University of Southampton |
| Invisio | V-Bio Ventures |
| IOFIX Ltd. | Ventac Partners |
| IP Group | Veryan Medical |
| Iratel Ventures | Vision Healthcare Consultancy |
| J A Kemp | Wellcome Trust |
| J&J Development Corp. | Wellington Partners |
| JAG Shaw Baker | Westwicke Partners |
| Jefferies | White & Case |
| Jefferies | Widecells |
| Johnson & Johnson Innovation | Woerwag Pharma GmbH & Co. |
| Jordi Ho | Wren Capital |
| JP Morgan | X-Ventures |
| Julz Co | Xanthella |
| Jupiter Diagnostics | Xbrane Biopharma |
| Karolinska Development | Xobaderm Ltd. |
| King's College London | Ysios Capital |
| King's Health Partners & King's Commercialisation Institute | Yuuwa Capital |
| Kreos Capital | Zilico |
| KU Leuven R&D |
